



## Commercial/Healthcare Exchange PA Criteria

*Effective: February 10, 2022*

**Prior Authorization:** Livtencity

**Products Affected:** Livtencity (maribavir) oral tablets

**Medication Description:** Livtencity is an antiviral drug with activity against CMV. Livtencity competitively inhibits pUL97, a protein kinase that plays a role in phosphorylating itself and other proteins essential to the viral replication cycle. Mutations in pUL54 DNA polymerase confer resistance to ganciclovir/valganciclovir, cidofovir, and foscarnet, but remain susceptible to Livtencity.

**Covered Uses:** Livtencity, an antiviral, is indicated for the treatment of adults and pediatric patients ( $\geq 12$  years of age and weighing  $\geq 35$  kg) with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir, or foscarnet.

**Exclusion Criteria:** N/A

**Required Medical Information:**

1. Diagnosis
2. Medical History
3. Past medications tried and failed

**Prescriber Restriction:** Prescribed by or in consultation with a hematologist, infectious diseases specialist, oncologist, or a physician affiliated with a transplant center.

**Age Restriction:** 12 years of age or older

**Coverage Duration:** 2 months

**Other Criteria:**

**Initial Approval Criteria**

1. **Cytomegalovirus Infection** – Treatment Approve for 2 months if the patient meets the following criteria (A, B, C, and D):
  - A. Patient weighs  $\geq 35$  kg; **AND**
  - B. Patient is post-transplant; **AND**  
Note: This includes patients who are post hematopoietic stem cell transplant or solid organ transplant.
  - C. Patient meets one of the following criteria (i **or** ii):
    - i. Patient has cytomegalovirus infection/disease that is refractory to treatment with at least one of the following: cidofovir, foscarnet, ganciclovir, or valganciclovir; **OR**
    - ii. Patient has significant intolerance to ganciclovir or valganciclovir; **AND**
  - D. The medication is not prescribed in conjunction with ganciclovir or valganciclovir

**References:**

January 2022



Confidential Information

This document is confidential and proprietary to ConnectiCare. Unauthorized use and distribution are prohibited.

Page 1 of 2



1. Livtency™ tablets [prescribing information]. Lexington, MA: Takeda; November 2021.
2. Maertens J, Cordonnier C, Jaksch P, et al. Maribavir for preemptive treatment of cytomegalovirus reactivation. N Engl J Med. 2019;381:1136-1147.

**Policy Revision history**

<b>Rev #</b>	<b>Type of Change</b>	<b>Summary of Change</b>	<b>Sections Affected</b>	<b>Date</b>
1	New Policy	New Policy	All	2/10/2022